CEMEDIC

CABA, Buenos Aires C1440CFD

2 studies enrolling now · 9 studies all time

What they study most

Cardiovascular Disease, Cardiovascular Risk, Chronic Kidney Disease, Heart Failure, Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2, Inflammation, Metastatic Breast Cancer, Obesity, Type 2 Diabetes, Type 2 Diabetes Mellitus

Studies at this site

• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels — Running, not enrolling
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity — Completed
• Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes — Completed
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk — Completed
• A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer — Withdrawn before enrolling